Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 44 for “"EGFR mutations"”.

  1. Regulation of Cell Signaling by Mig6 and Sprouty2 in Cancers With Egfr Mutations

    Epidermal growth factor receptor (EGFR) mutation and overexpression promote tumorigenesis in multiple cancers. Understanding the complex EGFR regulatory network is critical for developing effective therapeutic interventions. To this end, this work investigated the functions of two incompletely …

    penn Repository record for Regulation of Cell Signaling by Mig6 and Sprouty2 in Cancers With Egfr Mutations (opens in a new tab)

  2. MET-EGFR Dimerisation in Lung Adenocarcinoma is Dependent on EGFR Mutations and Altered by MET Kinase Inhibition

    … is extremely poor with few effective therapies. EGFR tyrosine kinase inhibitors (TKIs) have high response rates in patients with activating EGFR mutations and are now an established part of therapy in selected patients. Such advances herald a previously unprecedented enthusiasm for the …

    kings Repository record for MET-EGFR Dimerisation in Lung Adenocarcinoma is Dependent on EGFR Mutations and Altered by MET Kinase Inhibition (opens in a new tab) Download PDF for MET-EGFR Dimerisation in Lung Adenocarcinoma is Dependent on EGFR Mutations and Altered by MET Kinase Inhibition (opens in a new tab)

  3. EGFR ir ALK genų mutacijų paplitimas nesmulkiųjų ląstelių plaučių vėžiu sergančių pacientų populiacijoje /

    … The main predictive markers for NSCLC are mutations in the epidermal growth factor receptor gene (EGFR) and the anaplastic lymphoma kinase gene (ALK). The frequency of mutations in these genes varies in different countries; therefore, this study aimed to investigate the prevalence of EGFR …

    vilnius Repository record for EGFR ir ALK genų mutacijų paplitimas nesmulkiųjų ląstelių plaučių vėžiu sergančių pacientų populiacijoje / (opens in a new tab)

  4. Targeted Oncogene Mutation Detection in Non-Small Cell Lung Cancer by Multiplexed Array Mass Spectrometry Genotyping: Results of a Clinical Validation Study

    … discovery of cancer driver genes and somatic mutations in lung cancer patient sub-groups has seen the emergence of genetic abnormalities being used in the treatment of lung cancer as predictive bio-markers and molecular targets for targeted cancer therapy especially in Non-small Cell Lung …

    auckland-tech Repository record for Targeted Oncogene Mutation Detection in Non-Small Cell Lung Cancer by Multiplexed Array Mass Spectrometry Genotyping: Results of a Clinical Validation Study (opens in a new tab)

  5. EGFR testing: the reliability and validity of using cytology smears for molecular genetic testing

    Background: Most often EGFR mutation analysis is performed on formalin fixed paraffin embedded (FFPE) tissue however, alcohol-fixed cytology smears are a potential diagnostically useful source of DNA. Although the use of cytology specimens for EGFR testing has been investigated, new studies are …

    unsw Repository record for EGFR testing: the reliability and validity of using cytology smears for molecular genetic testing (opens in a new tab)

  6. Preclinical and clinical characterization of lung cancers with Exon 19 insertion

    The epidermal growth factor receptor (EGFR)-K745_E746insIPVAIK and others with rare PVAI amino-acid insertions are exon 19 insertion mutations (<1% of all EGFR mutations), which, at the structural modeling level, resemble EGFR tyrosine kinase inhibitor (TKI)-sensitizing mutants. An important unmet …

    bu Repository record for Preclinical and clinical characterization of lung cancers with Exon 19 insertion (opens in a new tab)

  7. Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution

    … activating epidermal growth factor receptor (EGFR) mutations, treated with tyrosine kinase inhibitors (TKIs), is not well-defined. In this retrospective study, the following aims were set out: 1) compare outcomes and profile of EGFRmut+ NSCLC patients to large cohorts of lung-cancer patients …

    calgary Repository record for Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution (opens in a new tab)

  8. Novel Therapeutic Strategies in Lung Cancer

    … many patients either do not have any common mutations for which there are already targetable agents, or they eventually become resistant to these compounds. As such, there is a high demand for new, effective methods of treating this disease as well as predicting patient prognosis and …

    usf Repository record for Novel Therapeutic Strategies in Lung Cancer (opens in a new tab)

  9. Synergistic Interaction of JTE-607 with EGFR-TKIs (Afatinib and Osimertinib) in Non-Small Cell Lung Cancer Cell Lines H1975 and HCC827: A Therapeutic Investigation

    … in cases with epidermal growth factor receptor (EGFR) mutations, including T790M. This study investigates the synergistic interaction of the small molecule inhibitor JTE-607 with Afatinib and Osimertinib to enhance TKI efficacy, to reduce dosage, and to minimize drug resistance. Methods: H1975 …

    buffalo Repository record for Synergistic Interaction of JTE-607 with EGFR-TKIs (Afatinib and Osimertinib) in Non-Small Cell Lung Cancer Cell Lines H1975 and HCC827: A Therapeutic Investigation (opens in a new tab)

  10. Novel therapeutic strategies for targeting EGFR mutated non-small cell lung cancer

    <p>Background: NSCLC patients with EGFR M+ tumours have marked clinical responses to EGFR-TKIs. Most patients experience tumour regrowth, as drug resistance emerges through on-target secondary EGFR-mutations or other activating mutations that reactivate the downstream signalling. However, a …

    oxford Repository record for Novel therapeutic strategies for targeting EGFR mutated non-small cell lung cancer (opens in a new tab)

  11. GATM is Involved in the Promotion of Drug Resistance in Lung Cancer

    … rate. Despite epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors being used as first-line treatment for patients with EGFR mutations, drug resistance frequently occurs in most patients. This is due to the involvement of a myriad of genes that help cancer cells survive against EGFR …

    ucf Repository record for GATM is Involved in the Promotion of Drug Resistance in Lung Cancer (opens in a new tab)

  12. Διερεύνηση της κλινικής σημασίας μοριακών δεικτών που συμμετέχουν σε κομβικά μονοπάτια της καρκινογένεσης του μη-μικροκυτταρικoύ καρκίνου του πνεύμονα

    … with flow cytometry, Ki67 labeling index and EGFR mutations in the same cohort of 96 patients with early operable NSCLC. Our results showed that low expression levels of γ-Η2ΑΧ represent an independent factor of better overall survival in patients with early operable NSCLC. Patients with high …

    greece Repository record for Διερεύνηση της κλινικής σημασίας μοριακών δεικτών που συμμετέχουν σε κομβικά μονοπάτια της καρκινογένεσης του μη-μικροκυτταρικoύ καρκίνου του πνεύμονα (opens in a new tab)

  13. Prediction of the binding free energies of inhibitors of epidermal growth factor receptor kinase and the identification of the dynamics thereof

    Epidermal Growth Factor Receptor (EGFR) kinase is a signalling protein implicated in a number of cancers, including non-small cell lung cancer (NSCLC). As well as activating mutations of EGFR kinase being oncogenic, the prognosis of NSCLC correlates with the impact of EGFR mutations on inhibitor …

    soton Download PDF for Prediction of the binding free energies of inhibitors of epidermal growth factor receptor kinase and the identification of the dynamics thereof (opens in a new tab)

  14. Systematic investigation of prognostic molecular biomarkers for retinopathies and targeted therapies in non-small cell lung cancer

    … a poor 5-year survival rate of 20-30 percent. EGFR mutations can make tumors initially responsive to tyrosine kinase inhibitors (TKIs) like Osimertinib (OS), but resistance often develops within 10-18 months. Research on EGFR dependent and independent mechanisms have been explored to identify …

    missouri Repository record for Systematic investigation of prognostic molecular biomarkers for retinopathies and targeted therapies in non-small cell lung cancer (opens in a new tab)

  15. Identifying SLAP2-TRIM21 as a Novel Endogenous Recycling Complex of EGFR in Lung Cancer

    The epidermal growth factor receptor (EGFR) is the most-studied member of the receptor tyrosine kinase (RTK) family of proteins, particularly as a driver oncogene in non-small cell lung cancer (NSCLC). Targeted therapeutic approaches to inhibiting EGFR activity with receptor tyrosine kinase …

    toronto-retro Repository record for Identifying SLAP2-TRIM21 as a Novel Endogenous Recycling Complex of EGFR in Lung Cancer (opens in a new tab)

  16. MACHINE LEARNING-GUIDED PREDICTION OF FUNCTIONAL OUTCOMES OF EGFR EXTRACELLULAR DOMAIN MUTATIONS IN COLORECTAL CANCER: IMPLICATIONS FOR CETUXIMAB RESISTANCE

    … (ECD) of the epidermal growth factor receptor (EGFR), have improved outcomes for RAS wild-type metastatic CRC patients. However, resistance to these therapies frequently arises through somatic mutations that alter the antibody-receptor interface. This project aims to develop a machine …

    jhu Repository record for MACHINE LEARNING-GUIDED PREDICTION OF FUNCTIONAL OUTCOMES OF EGFR EXTRACELLULAR DOMAIN MUTATIONS IN COLORECTAL CANCER: IMPLICATIONS FOR CETUXIMAB RESISTANCE (opens in a new tab)

  17. Targeting ferroptosis pathway to overcome erlotinib resistance

    … improve prognosis by acting on specific genetic mutations. Epidermal growth factor receptor (EGFR) is frequently hyperactivated in NSCLC, and EGFR tyrosine kinase inhibitors have been used clinically for decades to treat patients harbouring EGFR mutations. However, acquired resistance commonly …

    oxford Restricted access

  18. Deciphering spatial signaling networks using image-based multiplexed approaches

    … cases includes a subgroup of patients with EGFR mutations who can benefit from EGFR tyrosine kinase inhibitors (TKIs). However, patients can still develop acquired drug resistance due to the activation and crosstalk among signaling pathways. Protein-protein interactions (PPI) significantly …

    gatech Repository record for Deciphering spatial signaling networks using image-based multiplexed approaches (opens in a new tab)

  19. Modeling targeted therapy mechanisms and predictive biomarker discovery using human primary non-small cell lung cancer xenografts

    … the best studied example is targeting activating mutations of the epidermal growth factor receptor (EGFR) gene. Tyrosine kinase inhibitors (TKIs) have significantly improved clinically outcomes in lung cancer patients with these activating EGFR mutations. However, EGFR TKIs are not a cure as the …

    toronto-retro Repository record for Modeling targeted therapy mechanisms and predictive biomarker discovery using human primary non-small cell lung cancer xenografts (opens in a new tab)

Page 1 of 3